Early experience with the HeartMate 3 continuous-flow ventricular assist device in pediatric patients and patients with congenital heart disease: A multicenter registry analysis

O’Connor, Matthew J.; Lorts, Angela; Davies, Ryan R.; Fynn‐Thompson, Francis; Joong, Anna; Maeda, Keisuke; Mascio, Christopher E.; McConnell, Patrick I.; Mongé, Michael C.; Nandi, Deipanjan; Peng, David M.; Rosenthal, David N.; Sing, Ming; Sutcliffe, D.; VanderPluym, Christina; Viegas, Melita; Zafar, Farhan; Zinn, Matthew D.; Morales, David L.S.

doi:10.1016/j.healun.2020.02.007

Cited by 102 publications

(103 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There were no incidents of pump thrombosis or stroke and driveline infection occurred in four patients (11%). 8 These findings, similar to our report, attest to the antithrombotic characteristics of HM3 technology.…”

Section: Preoperative Evaluationsupporting

confidence: 91%

“…One of F I G U R E 3 Outflow graft de-airing F I G U R E 4 Radiograph demonstrating final ventricular assist device position within the thoracic cavity the most recent studies, procured from the ACTION registry, describes use of the HM3 in children and adults with CHD. 8 Among 35 patients in this series, 28 were under the age of 18, the youngest being 8.8 years of age. Fontan circulation was present in only five patients (not including the patient in this report).…”

Section: Preoperative Evaluationmentioning

confidence: 85%

“…Only recently have we seen reports of VAD use in patients with CHD, especially those at the lowest extremes of age and size. One of the most recent studies, procured from the ACTION registry, describes use of the HM3 in children and adults with CHD 8 . Among 35 patients in this series, 28 were under the age of 18, the youngest being 8.8 years of age.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Implantation of a HeartMate 3 ventricular assist device in a 21‐kg pediatric patient with Fontan failure

et al. 2020

View full text Add to dashboard Cite

Aims: The HeartMate 3 (HM3) ventricular assist device (VAD) is gaining popularity in adults due to a favorable risk profile. However, reports of HM3 use in children are limited, potentially due to concerns with device size. Materials and Methods: Here we report the successful use of an HM3-VAD as a bridge to transplantation in a 21 kg (BSA 0.84), an 8-year-old male child with Fontan failure on home inotropes. Results: Urgent VAD implantation was performed. The standard adult sewing ring was used. The tricuspid valve and papillary muscles were completely excised from the ventricular cavity to prevent inflow obstruction. The pump was placed in the left pleural space. Outflow graft and driveline implantation were routine. VAD function appeared excellent with a reduction in Fontan pressures and improved kidney and liver function. Reoperation was required once to rule out tamponade and twice to evacuate a recurrent right hemothorax. The patient was discharged 3 months later in good condition and underwent successful heart transplantation 10 months after VAD placement. Discussion: This report demonstrates the feasibility of HM3-VAD implantation in a 21-kg Fontan patient, suggesting HM3 size is not a prohibitive limitation at this weight.

show abstract

Section: Preoperative Evaluationsupporting

confidence: 91%

Section: Preoperative Evaluationmentioning

confidence: 85%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Implantation of a HeartMate 3 ventricular assist device in a 21‐kg pediatric patient with Fontan failure

et al. 2020

View full text Add to dashboard Cite

show abstract

“…22 Since its inception, ACTION has collaborated with over 44 centers resulting in substantial and quantifiable improvements in the outcomes and care processes for children supported by ventricular assist devices (VADs) and their families. 23 Although ACTION originally focused its efforts on children requiring VAD support, the network has recently expanded their scope to all elements of HF care, including the management of children listed for HT with or without VAD support. This expansion included the formation of the WOC in 2019 which includes physicians, nurses, a quality scientist, heart transplant patients, and their parents.…”

Section: Ac Ti On ' S Miss I Onmentioning

confidence: 99%

“…The primary benefit of this approach, which is aptly suited for high‐risk diseases affecting relatively small populations for whom large‐scale clinical trials are often not feasible, is the immediate and extensive impact on patients who cannot wait for clinical practice change to navigate slowly through traditional academic channels 22 . Since its inception, ACTION has collaborated with over 44 centers resulting in substantial and quantifiable improvements in the outcomes and care processes for children supported by ventricular assist devices (VADs) and their families 23 …”

Section: Action’s Missionmentioning

confidence: 99%

A coordinated approach to improving pediatric heart transplant waitlist outcomes: A summary of the ACTION November 2019 waitlist outcomes committee meeting

Hollander

Nandi

Bansal

et al. 2020

Pediatric Transplantation

Self Cite

View full text Add to dashboard Cite

The number of children needing heart transplantation (HT) continues to rise. 1 Although improvements in heart failure (HF) therapy, particularly durable mechanical support, have improved waitlist outcomes, much work remains to be done. Firstly, the number of children who die while waiting for a suitable donor organ remains high. Currently, around 13% children and 25% of infants on the HT waitlist will not survive to transplantation. 2 Among those who do survive to transplant, waitlist characteristics, including waitlist duration, available mechanical support options, and renal injury all contribute to post-transplant outcomes. 3-8 The waitlist phase of care has received considerable attention recently, including the recent publication of an International Society for Heart & Lung Transplantation (ISHLT) consensus statement on donor organ acceptability and other important papers. 9-19 Given that the unacceptably high waitlist mortality rate is likely a result of cumulative effect of several inefficiencies in care along the heart failure-transplant trajectory, multiple interventions at various

show abstract

Continuous‐Flow Left Ventricular Assist Devices: Perspective on Engineering and Pump Technology

Tang,

Pagani

2023

Textbook of Transplantation and Mechanical Support for End‐Stage Heart and Lung Disease

View full text Add to dashboard Cite

Early experience with the HeartMate 3 continuous-flow ventricular assist device in pediatric patients and patients with congenital heart disease: A multicenter registry analysis

Cited by 102 publications

References 13 publications

Implantation of a HeartMate 3 ventricular assist device in a 21‐kg pediatric patient with Fontan failure

Implantation of a HeartMate 3 ventricular assist device in a 21‐kg pediatric patient with Fontan failure

A coordinated approach to improving pediatric heart transplant waitlist outcomes: A summary of the ACTION November 2019 waitlist outcomes committee meeting

Continuous‐Flow Left Ventricular Assist Devices: Perspective on Engineering and Pump Technology

Contact Info

Product

Resources

About